Back to Search Start Over

Levosimendan Ameliorates Cardiopulmonary Function but Not Inflammatory Response in a Dual Model of Experimental ARDS.

Authors :
Rissel R
Gosling M
Kamuf J
Renz M
Ruemmler R
Ziebart A
Hartmann EK
Source :
Biomedicines [Biomedicines] 2022 Apr 29; Vol. 10 (5). Date of Electronic Publication: 2022 Apr 29.
Publication Year :
2022

Abstract

The calcium sensitiser levosimendan, which is used as an inodilator to treat decompensated heart failure, may also exhibit anti-inflammatory properties. We examined whether treatment with levosimendan improves cardiopulmonary function and is substantially beneficial to the inflammatory response in acute respiratory response syndrome (ARDS). Levosimendan was administered intravenously in a new experimental porcine model of ARDS. For comparison, we used milrinone, another well-known inotropic agent. Our results demonstrated that levosimendan intravenously improved hemodynamics and lung function in a porcine ARDS model. Significant beneficial alterations in the inflammatory response and lung injury were not detected.

Details

Language :
English
ISSN :
2227-9059
Volume :
10
Issue :
5
Database :
MEDLINE
Journal :
Biomedicines
Publication Type :
Academic Journal
Accession number :
35625767
Full Text :
https://doi.org/10.3390/biomedicines10051031